HealthNotableEmerging
4.8
Novo Nordisk shifts focus to oral weight-loss drugs amid GLP-1 competition
El EspectadorLO·DK·about 7 hours ago
GLP-1 receptor agonists, originally for diabetes and obesity, are being studied for their effect on alcohol cravings and addiction. Early evidence suggests they reduce cravings but may also dull overall reward sensitivity, raising quality-of-life concerns. The mechanism and long-term implications remain uncertain.